(MENAFN- ProactiveInvestors)Raymond Akers executive chairman of Akers Biosciences Inc (NASDAQ:AKER LON:AKR) says the company has 'paved the way for significant sales of our flagship product both in the US and China' and has 'already started to see the results'. The firm announced today that orders for its rapid heparin allergy test total more than US$3mln with $2.5mln from China as well as a 70% rise in demand from the US in the first quarter. Akers says with the expanded order book that he expects to be cash generative in the second half of this year.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.